Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
15.9M
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
608K
-
Shares change
-
+373K
-
Total reported value, excl. options
-
$214K
-
Value change
-
+$134K
-
Number of buys
-
8
-
Number of sells
-
-6
-
Price
-
$0.35
Significant Holders of ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (ADIL) as of Q3 2025
19 filings reported holding ADIL - ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share as of Q3 2025.
ADIAL PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (ADIL) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 608K shares
of 15.9M outstanding shares and own 3.82% of the company stock.
Largest 10 shareholders include GEODE CAPITAL MANAGEMENT, LLC (164K shares), VANGUARD GROUP INC (156K shares), CITADEL ADVISORS LLC (144K shares), Manchester Capital Management LLC (48.1K shares), BlackRock, Inc. (27.8K shares), UBS Group AG (18.8K shares), TWO SIGMA SECURITIES, LLC (12.8K shares), JANE STREET GROUP, LLC (12.3K shares), HRT FINANCIAL LP (11.2K shares), and PRIVATE MANAGEMENT GROUP INC (10K shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.